Therapeutic Drug Monitoring of Anti-TNFα Inhibitors: A Matter of Cut-Off Ranges.
adalimumab
adalimumab antibodies
anti-infliximab antibodies
inflammatory bowel disease
infliximab
therapeutic drug monitoring
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
27 Jun 2023
27 Jun 2023
Historique:
received:
06
06
2023
revised:
21
06
2023
accepted:
24
06
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Therapeutic drug monitoring (TDM) is a useful tool for optimising the use of anti-TNFα inhibitors in patients with inflammatory bowel diseases (IBDs). Recently, point-of-care methods for the quantification of drug levels and anti-drug antibodies (ADAs) have been developed to overcome the limitations of conventional enzyme-linked immunoabsorbent assays (ELISAs). Here, we evaluated the performance, interchangeability, and agreement between an automated ELISA-based immunoassay (CHORUS Promonitor) and the lateral flow assay (RIDA
Identifiants
pubmed: 37514022
pii: pharmaceutics15071834
doi: 10.3390/pharmaceutics15071834
pmc: PMC10386140
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1580-1588.e3
pubmed: 28365486
J Pharm Biomed Anal. 2020 Jan 5;177:112842
pubmed: 31526960
Aliment Pharmacol Ther. 2018 Jun;47(11):1571-1573
pubmed: 29878425
Frontline Gastroenterol. 2016 Oct;7(4):289-300
pubmed: 28839870
Stat Methods Med Res. 1999 Jun;8(2):135-60
pubmed: 10501650
Clin Gastroenterol Hepatol. 2021 Apr;19(4):839-841.e2
pubmed: 32147594
J Pediatr Gastroenterol Nutr. 2019 Oct;69(4):474-479
pubmed: 31149938
Clin Gastroenterol Hepatol. 2019 Aug;17(9):1655-1668.e3
pubmed: 30928454
Gastroenterology. 2015 Jun;148(7):1320-9.e3
pubmed: 25724455
Cytokine. 2020 Feb;126:154859
pubmed: 31629989
Ther Drug Monit. 2020 Dec;42(6):821-828
pubmed: 32947553
Aliment Pharmacol Ther. 2017 Dec;46(11-12):1037-1053
pubmed: 29027257
Autoimmun Rev. 2013 May;12(7):703-8
pubmed: 23207283
Gastroenterology. 2021 Apr;160(5):1570-1583
pubmed: 33359090
Aliment Pharmacol Ther. 2016 Oct;44(7):684-92
pubmed: 27507790
Therap Adv Gastroenterol. 2017 Sep;10(9):651-660
pubmed: 28932267
Int J Mol Sci. 2019 May 23;20(10):
pubmed: 31126015
Frontline Gastroenterol. 2017 Oct;8(4):236-242
pubmed: 29067148
Gastroenterology. 2022 Apr;162(5):1512-1524
pubmed: 35167865
J Crohns Colitis. 2020 Oct 07;:
pubmed: 33026087
Dig Dis Sci. 2018 Oct;63(10):2714-2721
pubmed: 29948562
Pathology. 2021 Jun;53(4):508-514
pubmed: 33272693
Ther Drug Monit. 2013 Aug;35(4):530-8
pubmed: 23765033
Aliment Pharmacol Ther. 2012 Oct;36(8):765-71
pubmed: 22928581
Autoimmun Rev. 2017 Jun;16(6):564-575
pubmed: 28411169
Clin Chem Lab Med. 2019 Nov 26;57(12):1906-1914
pubmed: 31085742
J Gastroenterol. 2017 May;52(5):535-554
pubmed: 28275925
Am J Gastroenterol. 2021 Oct 1;116(10):2014-2025
pubmed: 34388143
Therap Adv Gastroenterol. 2018 Jan 21;11:1756283X17750355
pubmed: 29383030
Curr Gastroenterol Rep. 2018 Apr 5;20(5):18
pubmed: 29623442
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571